tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2021-99-8-7-12tiblj-1557Research ArticleОБЗОРREVIEWСаркоидоз и COVID-19Sarcoidosis and COVID-19ДобинВ. Л.DobinV. L.

Добин Виталий Лазаревич, доктор медицинских наук, профессор, заведующий кафедрой фтизиатрии с курсом лучевой диагностики.

Тел.: 8 (4912) 92-01-51

390046, г. Рязань, Голенченское шоссе, д. 15

Dobin Vitaly L., Doctor of Medical Sciences, Professor, Head of Phthisiology Department with Training in X-ray Diagnostics

Phone: +7 (4912) 92-01-51

15, Golenchenskoye Rd, Razyan, 390046

viladob@gmail.comПанинИ. В.PaninI. V.

Панин Илья Владимирович, кандидат медицинских наук, доцент кафедры фтизиатрии с курсом лучевой диагностики

390046, г. Рязань, Голенченское шоссе, д. 15

Panin Ilya V., Candidate of Medical Sciences, Associate Professor of Phthisiology Department with Training in X-ray Diagnostics 

15, Golenchenskoye Rd, Razyan, 390046

iliavpanin@gmail.comФГБОУ ВО «Рязанский государственный медицинский университет им. акад. И. П. Павлова»РоссияRazyan State Medical University Named after Academician I. P. PavlovRussian Federation202107092021998712Copyright © Добин В.Л., Панин И.В., 20212021Добин В.Л., Панин И.В.Dobin V.L., Panin I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1557

В обзоре проанализирован 21 литературный источник, содержащий сведения по вопросам патогенеза, клинического течения, особенностей лечения (саркоидоза в эру CОVID-19) и прогностическим аспектам саркоидоза на фоне пандемии CОVID-19.

The review analyzes 21 publications on sarcoidosis pathogenesis, clinical course, treatment characteristics (sarcoidosis in the COVID-19 era), and prognostic aspects during the COVID-19 pandemic.

CОVID-19саркоидозCOVID-19sarcoidosisReferencesГудима Г. О., Хаитов Р. М., Кудлай Д. А., Хаитов М. Р. Молекулярно-иммунологические аспекты диагностики, профилактики и лечения коронавирусной инфекции // Иммунология. - 2021. - Т. 42, № 3. - С. 198-210. DOI: https://doi.org/10.33029/0206-4952-2021-42-3-198-210.Gudima G. O., Khaitov R. M., Kudlay D. A., Khaitov M. R. Molecular immunological aspects of diagnosis, prevention and treatment of coronavirus infection. Immunologiya, 2021, vol. 42, no. 3, pp. 198-210. (In Russ.) doi: https://doi.org/10.33029/0206-4952-2021-42-3-198-210.Козлов В. А., Савченко А. А., Кудрявцев И. В., Козлов И. Г., Кудлай Д. А., Продеус А. П., Борисов А. Г. Клиническая иммунология. - Красноярск: Поликор, 2020. - 386 с. DOI: 10.17513/np.438.Kozlov V. A., Savchenko А. А., Kudryavtsev I. V., Kozlov I. G., Kudlay D. A., Prodeus А. Р, Borisov А. G. Klinicheskaya immunologiya. [Clinical immunology]. Krasnoyarsk, Polikor Publ., 2020, 386 p. doi: 10.17513/np.438.Старшинова А. А., Кушнарева Е. А., Кудлай Д. А., Довгалюк И. Ф. Возможности лечения больных с COVID-19: анализ данных литературы // Трансляционная медицина. - 2020. - Т. 7. № 3. - С. 30-37.Starshinova А. А., Kushnareva E. A., Kudlay D. A., Dovgalyuk I. F. Treatment options for COVID-19 patients: analysis of literature data. Translyatsionnaya Meditsina, 2020, vol. 7, no. 3, pp. 30-37. (In Russ.)Cacciapaglia Е, Manfredi A., Erre G. et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 / global rheumatology alliance physician-reported registry // Ann. Rheum. Dis. - 2020. - Vol. 79, № 7. - P. 859-866. doi: 10.1136/annrheumdis-2020-217871.Cacciapaglia E., Manfredi A., Erre G. et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 / global rheumatology alliance physician-reported registry. Ann. Rheum. Dis., 2020, vol. 79, no. 7, pp. 859-866. doi: 10.1136/annrheumdis-2020-217871.Drake T. M., Docherty A. B., Harrison E. M. et al. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study // Am. J. Respir. Crit. Care Med. - 2020. - Vol. 202, № 12. - P 1656-1665. doi: 10.1164/rccm.202007-2794OC. PMID: 33007173; PMCID: PMC7737581.Drake T. M., Docherty A. B., Harrison E. M. et al. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. Am. J. Respir. Crit. Care Med., 2020, vol. 202, no. 12, pp. 1656-1665. doi: 10.1164/rccm.202007-2794OC. PMID: 33007173; PMCID: PMC7737581.Flood R. M., Conway R., Kirby C., Gheta D., Kane D. J., Mullan R. H. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19. Global Rheumatology Alliance physician-reported registry // Ann. Rheum Dis. - 2020. - Aug 19. http: annrheumdis-2020-218733. doi: 10.1136/annrheumdis-2020-218733. Epub ahead of print. PMID: 32816697.Flood R. M., Conway R., Kirby C., Gheta D., Kane D. J., Mullan R. H. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19. Global Rheumatology Alliance physician-reported registry. Ann. Rheum Dis., 2020, Aug 19. http: annrheumdis-2020-218733. doi: 10.1136/annrheumdis-2020-218733. Epub ahead of print. PMID: 32816697.Gagiannis Daniel, Steinestel Julie, Hackenbroch Carsten, Schreiner Benno, Michael Hannemann et al. Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD) // Front. Immunol. Actions. - 2020. - Vol. 11. - P. 587517. doi: 10.3389/fimmu.2020.587517.Gagiannis Daniel, Steinestel Julie, Hackenbroch Carsten, Schreiner Benno, Michael Hannemann et al. Clinical, serological, and histopathological similarities between severe COVID-19 and acute exacerbation of connective tissue disease-associated interstitial lung disease (CTD-ILD). Front. Immunol. Actions, 2020, vol. 11, pp. 587517. doi: 10.3389/fimmu.2020.587517.Gianfrancesco M., Hyrich K. L., Al-Adely S., Carmona L. et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19. Global Rheumatology Alliance physician-reported registry // Ann Rheum Dis. - 2020. - Vol. 79, № 7. - P. 859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29. PMID: 32471903; PMCID: PMC7299648.Gianfrancesco M., Hyrich K. L., Al-Adely S., Carmona L. et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19. Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis., 2020, vol. 79, no. 7, pp. 859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29. PMID: 32471903; PMCID: PMC7299648.Gyorfi A. H., Kopp M., May M., Vetter M., Uder M., Kremer A. E. et al. Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis // Ann. Rheum. Dis. - 2020. Doi:10.1136/annrheumdis-2020-218258 PubMed.Gyorfi A. H., Kopp M., May M., Vetter M., Uder M., Kremer A. E. et al. Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis. Ann. Rheum. Dis., 2020, doi:10.1136/annrheumdis-2020-218258 PubMed.Huang H., Zhang M., Chen C., Zhang H., Wei Y., Tian J. et al. Clinical characteristics of COVID-19 in patients with preexisting ILD: A retrospective study in a single center in Wuhan, China // J. Med. Virol. - 2020. - Vol. 92, № 11. - P 2742-2750. doi: 10.1002/jmv.26174. Epub 2020 Aug 2. PMID: 32533777; PMCID: PMC7322991.Huang H., Zhang M., Chen C., Zhang H., Wei Y., Tian J. et al. Clinical characteristics of COVID-19 in patients with preexisting ILD: A retrospective study in a single center in Wuhan. China. J. Med. Virol., 2020, vol. 92, no. 11, pp. 2742-2750. doi: 10.1002/jmv.26174. Epub 2020 Aug 2. PMID: 32533777; PMCID: PMC7322991.Karahan S., Cetinkaya A., Aydin K., Aslan Sirakaya H. Comment on: ’Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19. Global Rheumatology Alliance physician // Ann. Rheum. Dis. - 2020. - Jul 21. http: annrheumdis-2020 - 18497. doi: 10.1136/annrheumdis-2020-218497. Epub ahead of print. PMID: 32719043.Karahan S., Cetinkaya A., Aydin K., Aslan Sirakaya H. Comment on: ’Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19. Global Rheumatology Alliance physician. Ann. Rheum. Dis., 2020, Jul 21. http: annrheumdis-2020-218497. doi: 10.1136/annrheumdis-2020-218497. Epub ahead of print. PMID: 32719043.Li E, Li W, Farzan M., Harrison S. C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor // Science. - 2005. -Vol. 309. - P. 1864-1868.Li E., Li W., Farzan M., Harrison S. C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science, 2005, vol. 309, pp. 1864-1868.Li X., Zhuang J., Rayford H., Zhang H., Shu R., Uhal B. D. Attenuation of bleomycin-induced pulmonary fibrosis by intratracheal administration of antisense oligonucleotides against angiotensinogen mRNA // Curr. Pharm. Des. - 2007. - Vol. 13, № 12. - P. 1257-1268. doi: 10.2174/138161207780618867. PMID: 17504234.Li X., Zhuang J., Rayford H., Zhang H., Shu R., Uhal B. D. Attenuation of bleomycin-induced pulmonary fibrosis by intratracheal administration of antisense oligonucleotides against angiotensinogen mRNA. Curr. Pharm. Des., 2007, vol. 13, no. 12, pp. 1257-1268. doi: 10.2174/138161207780618867. PMID: 17504234.Malkova A., Kudlay D., Kudryavtsev I., Starshinova A., Yablonskiy P., Shoenfeld Y. Immunogenetic Predictors of Severe COVID-19 // Vaccines. - 2021. - Vol. 9, № 211. doi.org/10.3390/vaccines9030211.Malkova A., Kudlay D., Kudryavtsev I., Starshinova A., Yablonskiy P., Shoenfeld Y. Immunogenetic Predictors of Severe COVID-19. Vaccines, 2021, vol. 9, no. 211. doi.org/10.3390/vaccines9030211.Manansala M., Ascoli C., Alburquerque A. G., Perkins D., Mirsaedi M., Finn P., Sweiss N. J. Case Series: COVID-19 in african american patients with sarcoidosis // Front Med (Lausanne). - 2020. - № 7. - P. 588527. doi: 10.3389/fmed.2020.588527. PMID: 33251236; PMCID: PMC7672207.Manansala M., Ascoli C., Alburquerque A. G., Perkins D., Mirsaedi M., Finn P., Sweiss N.J. Case Series: COVID-19 in african american patients with sarcoidosis. Front Med (Lausanne), 2020, no. 7, pp. 588527. doi: 10.3389/fmed.2020.588527. PMID: 33251236; PMCID: PMC7672207.Morgenthau A. S., Levin M. A., Freeman R., Reich D. L., Klang E. Moderate or severe impairment in pulmonary function is associated with mortality in sarcoidosis patients infected with SARS-CoV-2 // Lung. - 2020. - Vol. 198, № 5. - P. 771-775. doi:10.1007/s00408-020-00392-9.Morgenthau A. S., Levin M. A., Freeman R., Reich D.L., Klang E. Moderate or severe impairment in pulmonary function is associated with mortality in sarcoidosis patients infected with SARS CoV 2. Lung, 2020, vol. 198, no. 5, pp. 771-775. doi:10.1007/s00408-020-00392-9.Recombinant human angiotensin - converting 2 (cha ACE2) as a treatment for patients with COVID-19 (APNO1-COVID-19) // Clinical. Trials. http: qov Identitifier NCT04335136.Recombinant human angiotensin - converting 2 (cha ACE2) as a treatment for patients with COVID-19 (APNO1-COVID-19). Clinical. Trials. http: qov Identitifier NCT04335136.Southern B. D. Patients with interstitial lung disease and pulmonary sarcoidosis are at high risk for severe illness related to COVID-19 // Clev. Clin. J. Med. - 2020. doi: 10.3949/ccjm.87a.ccc026.Southern B. D. Patients with interstitial lung disease and pulmonary sarcoidosis are at high risk for severe illness related to COVID-19. Clev. Clin. J. Med., 2020, doi: 10.3949/ccjm.87a.ccc026.Sweiss N. J., Korsten P, Syed H. J. et al. When the game changes: guidance to adjust sarcoidosis management during the COVID-19 pandemic // Chest. - 2020. - 29 April. DOI: 10.1016/j.chest.2020.04.033. Epub ahead of print.Sweiss N. J., Korsten P., Syed H. J. et al. When the game changes: guidance to adjust sarcoidosis management during the COVID-19 pandemic. Chest, 2020, 29 April. doi: 10.1016/j.chest.2020.04.033. Epub ahead of print.Uhal B. D., Dang M., Dang V., Llatos R., Cano E., Abdul-Hafez A. et al. Cell cycle dependence of ACE-2 explains downregulation in idiopathic pulmonary fibrosis // Eur. Respir. J. - 2013. - Vol. 42. - P. 198-210. DOI:10.1183/09031936.00015612.Uhal B. D., Dang M., Dang V., Llatos R., Cano E., Abdul-Hafez A. et al. Cell cycle dependence of ACE-2 explains downregulation in idiopathic pulmonary fibrosis. Eur. Respir. J., 2013, vol. 42, pp. 198-210. DOI:10.1183/09031936.00015612.Wong A. W, Fidler L., Marcoux V, Johannson K. A., Assayag D., Fisher J. H. et al. Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the coronavirus disease 2019 pandemic // Chest. - 2020. - Vol. 158. - P. 1069-1078.Wong A. W., Fidler L., Marcoux V, Johannson K. A., Assayag D., Fisher J. H. et al. Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the coronavirus disease 2019 pandemic. Chest, 2020, vol. 158, pp. 1069-1078.

The authors declare that there are no conflicts of interest present.